

European Heart Journal Supplements

Volume 24 Supplement L December 2022

Time for change

S. Zieroth and R. Ferrari

L1

Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come

I.L. Piña, G.T. Gibson, S. Zieroth, and R. Kataria

L2

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?

K.F. Docherty, A. Bayes-Genis, J. Butler, A.J.S. Coats, M.H. Drazner, E. Joyce, and C.S.P. Lam

L10

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines

D. Tomasoni, M. Adamo, B. Bozkurt, P. Heidenreich, T. McDonagh, G.M.C. Rosano, S.A. Virani, S. Zieroth, and M. Metra

L20

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe

N. Marx, A.Y.Y. Cheng, R. Agarwal, S.J. Greene, and H. Abuhantash

L29

Getting ahead of the game: in-hospital initiation of HFrEF therapies

J. Biegus, Y. Moayed, C. Saldarriaga, and P. Ponikowski

L38

Representation matters: a call for inclusivity and equity in heart failure clinical trials

N. Reza, A. Nayak, S.C. Lewsey, and E.M. DeFilippis

L45

A rationale for dedicated trials of combination therapy in heart failure

V. Blumer and M. Vaduganathan

L49

Dear colleagues: enough with the men-only author panels

H.G.C. Van Spall, R. Mehran, and J.L. Januzzi

L53

